FDA approves new oral antibiotic Nuzolvence for gonorrhea, Sanofi faces drug delays

The FDA approved a novel oral antibiotic, Nuzolvence, to treat gonorrhea, marking a significant advancement against antibiotic-resistant strains of the infection. This approval follows a previous FDA decision for another gonorrhea drug and addresses the growing challenge of evolving bacteria that evade current treatments, with Nuzolvence being the first new drug specifically targeting gonorrhea in decades. The development of Nuzolvence was a result of a public-private partnership, highlighting collaborative efforts to combat antibiotic resistance.